Company news
ABVC BioPharma, Inc. news in 2022
ABVC BioPharma, Inc.'s news releases, calls and decks from 2022, newest first.
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
November 16, 2022
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
November 13, 2022
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
October 4, 2022
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
September 22, 2022
ABVC Biopharma Announces Letter to Shareholders
September 12, 2022
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
September 8, 2022
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
August 14, 2022
ABVC BioPharma Provides Vitargus® Update
August 1, 2022
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
July 12, 2022
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
June 20, 2022
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
June 15, 2022
ABVC BioPharma Announces Termination of Two Contracts
June 9, 2022
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
May 31, 2022
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
May 15, 2022
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
May 12, 2022
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
May 11, 2022
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
May 9, 2022
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
May 4, 2022
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
May 2, 2022
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
April 27, 2022
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
April 25, 2022
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
March 30, 2022
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
February 1, 2022
ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites
January 4, 2022